Lamotrigine is used to treat seizures in people with epilepsy and to prevent mood episodes (depression and mania) in people with bipolar disorder.[2] Lamictal is currently approved and in use across 40 indications[4].[1]
Lamictal is one of 757 small molecule programs targeting Bilateral tonic-clonic seizure. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
1050 competitors in Asthma
Lamictal
Veramyst
Xolair
Singulair
Nucala
Cinqair
Dupixent
Asmanex
Celexa
Spiriva
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Dec 27, 1994
LAMICTAL
NDA NDA020241
Sep 8, 2000
LAMICTAL CD
NDA NDA020764
May 8, 2009
LAMICTAL ODT
NDA NDA022251
May 29, 2009
LAMICTAL XR
NDA NDA022115
Sep 16, 2025
SUBVENITE
NDA NDA218879
Sources
Details